Key Highlights
- Serina Therapeutics climbed 39.45% during after-hours trading, reaching $1.78 from a regular-session close of $1.28.
- The biotech firm revealed a $15 million private placement set to close March 20, with an additional $15 million tranche available by April 30.
- Full warrant exercise could generate an extra $33.3 million, potentially funding operations through the second half of 2027.
- Shares were priced at $2.25 each — representing a 68% premium over the March 17 closing price.
- Greg Bailey, a board director with ties to Pfizer’s $11.6B Biohaven purchase and $14B Medivation transaction, will assume the Co-Chairman position.
Serina Therapeutics (SER) experienced a dramatic after-hours rally Wednesday, climbing nearly 40% following the small-cap biotechnology company’s announcement of a private placement that could generate up to $63.3 million.
Serina Therapeutics, Inc., SER
The substantial price movement occurred after the closing bell, when Serina disclosed that the initial $15 million tranche is scheduled to close on March 20, 2026. A subsequent tranche of up to $15 million is projected to close on or before April 30.
Shares rose from a regular-session close of $1.28 — which represented a 4.48% decline for the day — to $1.78 during after-hours activity.
The offering establishes a price of $2.25 per share, reflecting a 68% premium over the March 17 closing figure. Each share or pre-funded warrant includes a half-warrant allowing stock purchase at $5.00 per share. These warrants carry a four-year term and, upon full exercise, could contribute an additional $33.3 million, elevating the total possible capital raise to $63.3 million.
This type of financial runway expansion carries significant implications for a clinical-stage enterprise. Serina indicates the capital would sustain its operations into the second half of 2027.
Prominent Co-Chairman Enhances Company Standing
The financing round is spearheaded by Greg Bailey, M.D., a current board member who will now assume the Co-Chairman role alongside existing chair Simba Gill, Ph.D.
Bailey brings substantial experience to the position. He participated as an early investor in Biohaven Ltd., which Pfizer acquired in 2022 for approximately $11.6 billion, and Medivation, which Pfizer purchased in 2016 for $14 billion.
Investors took note of this background. When someone with Bailey’s credentials leads a financing round, biotech market participants typically pay attention.
Capital Allocation Strategy
The raised funds will support Serina’s SER-252 registrational study, an ongoing Phase 1b trial focused on advanced Parkinson’s disease. Patient enrollment is underway at clinical sites in Australia and the United States.
SER-252 is advancing through the FDA’s 505(b)(2) regulatory pathway, which CEO Steve Ledger characterized as “capital-efficient.” The study has already administered its first patient dose.
Serina anticipates Cohort 1 safety data will enable progression to Cohort 2 in Q3 2026. Topline results from the single-ascending dose arm are expected during the first half of 2027.
The therapeutic candidate addresses approximately 250,000 advanced Parkinson’s patients across the U.S. and Europe who experience insufficient symptom control with existing treatment options.
Wednesday’s post-market rally stands in contrast to the stock’s broader performance trajectory. SER has traded within a 52-week range of $1.22 to $7.92 and has fallen 71.11% over the trailing 12 months. The company maintains a market capitalization of just $13.65 million, while its RSI registers at 29.86 — indicating deeply oversold conditions.
SER concluded Wednesday’s regular trading session at $1.28, reflecting a 4.48% decline for the day.
